Q4 Earnings Forecast for Cryoport Issued By Leerink Partnrs

Cryoport, Inc. (NASDAQ:CYRX - Free Report) - Equities researchers at Leerink Partnrs issued their Q4 2026 earnings per share (EPS) estimates for Cryoport in a report released on Wednesday, April 16th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings of ($0.16) per share for the quarter. The consensus estimate for Cryoport's current full-year earnings is ($0.99) per share.

A number of other brokerages also recently issued reports on CYRX. Guggenheim reissued a "buy" rating and set a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. UBS Group lifted their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Finally, Roth Mkm reiterated a "buy" rating and issued a $15.00 price target on shares of Cryoport in a research note on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $11.67.

Cryoport Stock Performance

Shares of NASDAQ:CYRX traded up $0.09 on Friday, reaching $5.65. 206,302 shares of the company's stock were exchanged, compared to its average volume of 542,930. Cryoport has a twelve month low of $4.58 and a twelve month high of $17.41. The company has a fifty day moving average of $5.94 and a 200-day moving average of $6.98. The company has a market capitalization of $281.99 million, a price-to-earnings ratio of -1.67 and a beta of 1.81. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. During the same quarter last year, the firm earned ($0.29) earnings per share.

Insiders Place Their Bets

In related news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 19,830 shares of company stock valued at $118,353 in the last 90 days. Corporate insiders own 10.10% of the company's stock.

Institutional Investors Weigh In On Cryoport

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in Cryoport by 23.8% during the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock worth $476,000 after purchasing an additional 15,036 shares during the last quarter. GAMMA Investing LLC raised its stake in Cryoport by 4,434.6% during the first quarter. GAMMA Investing LLC now owns 14,556 shares of the company's stock worth $89,000 after buying an additional 14,235 shares during the last quarter. PharVision Advisers LLC acquired a new position in Cryoport in the fourth quarter valued at $259,000. Squarepoint Ops LLC lifted its holdings in Cryoport by 208.4% in the fourth quarter. Squarepoint Ops LLC now owns 36,499 shares of the company's stock valued at $284,000 after buying an additional 24,665 shares during the period. Finally, State of Wyoming boosted its position in Cryoport by 170.2% during the fourth quarter. State of Wyoming now owns 32,426 shares of the company's stock valued at $252,000 after acquiring an additional 20,427 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.